poly-ICR vaccine adjuvant (Akela)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namepoly-ICR vaccine adjuvant (Akela)
Drug Alias Namepoly(inosinic-cytidylic) acid-poly argininepoly-ICR vaccine adjuvant (Nventa)poly-ICRpoly IC-poly arginine
ClassificationBiologics
Mechanisms of ActionToll like receptor 3 agonists
TargetsToll like receptor 3
Therapy Area/IndicationsVaccination
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNventa Biopharmaceuticals Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAkela Pharma IncNventa Biopharmaceuticals Corp
Active IndicationsN/A
Inactive IndicationsVaccination

Other Information

ATC CodeN/A
Related LinksN/A